

Quick-Med Technologies



CORPORATE PROFILE — February 2012

Quick-Med Technologies, Inc. (OTCQB: QMDT) is a life sciences company delivering advanced antimicrobial technologies for infection prevention and control in the healthcare and consumer markets.

Hospital / Community Infections: A preventable epidemic - A huge cost

- 100,000 deaths annually in US
- \$10 Billion additional cost
- "Super bug" threats growing
- Older technologies lagging/ineffective

Innovative solutions in demand

The Quick-Med Opportunity

- New powerful technology
- First FDA clearance 2009
- Early adoption by key firms
- Excellent pipeline



First Fundamentally New Technology in 20 Years


- Cleared by FDA as "De Novo" (nothing like it before)
- Permanently bound, non-leaching, powerful, with no risk of resistance
- Kills MRSA, VRE, E. coli and other dangerous species
- Order of magnitude lower cost
- Patent protected

Large Target Markets


- Wound care - \$14 Billion
- Catheters - \$13 Billion
- Medical/hygiene textiles - \$8 Billion
- Hand sanitizers - \$2 Billion

Our Patented Difference:

- ◆ New type of molecule — not previously used in health care
- ◆ Bonded to the substrate
- ◆ Powerful while avoiding problems of older technologies



Staphylococcus aureus



Before After

RAPID EXECUTION: Early Adoption by Industry Leaders and Innovators

- ◆ **Traditional wound care**
 - North America license: Derma Sciences
 - OTC license: leading consumer healthcare company
 - India license: Viridis BioPharma
- ◆ **Advanced wound care**
 - NIMBUS foam dressings: Viridis BioPharma
 - NIMBUS film dressing: FDA clearance pending
- ◆ **Medical adhesives**
 - License Agreement: Avery Dennison
- ◆ **Catheters**
 - Joint development: Foster/PolyMedex (pioneer in medical resins and tubing)
- ◆ **Business development in progress**
 - Additional wound care providers
 - Medical textiles
 - Military textiles
 - Consumer apparel

Quick-Med Technologies, Inc.

902 NW 4th Street • Gainesville, Florida 32601 • (888) 835-2211 • www.quickmedtech.com





Quick-Med Technologies, Inc.

OTCQB: QMDT

MANAGEMENT TEAM

Ladd Greeno

Chief Executive Officer

Jerry Olderman, Ph.D.

VP, Research & Development

Nam Nguyen, CPA

Chief Financial Officer

Roy Carr

Business Development

SCIENTIFIC ADVISORS

Greg Shultz, Ph.D.

*Director of Institute for Wound Research, University of Florida
Past President,
Wound Healing Society*

Chris Batich, Ph.D.

Professor of Materials Science and Engineering, University of Florida



COMPETITIVE ADVANTAGES drive early adoption by key firms

Characteristic	Quick-Med	Silver	Triclosan
Effectiveness	High	High	Medium
Leaching	No	Yes	Yes
Bacterial Resistance	No	Documented	Documented
Economics	Low Cost	Expensive	Medium Cost
Safety/Ecology Concerns	No	Yes*	Yes
Patent Protected	Yes	No	No

*Impedes wound healing / environmental questions on nanosilver

HIGHLY SCALABLE BUSINESS MODEL

- Technology development and out-licensing
- High margin, high leverage business model
- Limited infrastructure (no manufacturing, no inventory carrying costs)
- Investments in R&D and partnering to maximize technology value
- Patented technologies licensed to leading companies, addressing large markets
- Customers address market needs without significant capital investment

TECHNOLOGY PIPELINE



Growth and Value Creation : Goals and Metrics

Intermediate term goals (3- 5 years)

- Partner with select market leaders
- >\$25 million Revenue
- 60% gross margins
- >\$250 million Market Cap

Long term franchise opportunity

- Supplier of choice – antimicrobial technology worldwide
- Presence in a broad range of healthcare and consumer markets
- \$ 300+ million revenue
- \$ 1+ billion Enterprise Value

J. Ladd Greeno
Chief Executive Officer
(888) 835.2211 Ext 102

lgreeno@quickmedtech.com

Nam H. Nguyen
Chief Financial Officer.
(888) 835.2211 Ext 104

nnguyen@quickmedtech.com

© 2012 Quick-Med Technologies, Inc.

This fact sheet and oral statements made with respect to information contains forward-looking statements (statements which are not statements of historical facts). Any statements contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "expects", "plans", "believes", "anticipates", "intends", "estimates", or statements concerning potential opportunities or variations thereof or comparable terminology or the negative thereof should be construed as forward-looking statements involving risks and uncertainties, including without limitation the launch and approval of the potential products described herein and the Company's results of operations. This fact sheet is provided for informational purposes only and is not a solicitation to invest in the Company. The Company is also subject to other risks as detailed from time-to-time in the Company's SEC filings. The fact sheet includes microbiology data to assist in technology evaluation. Data presented herein were collected using standard laboratory methods and are presented solely to substantiate the efficacy of Quick-Med's antimicrobial technologies. Display of this data is not intended to be a public health claim.